Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Current issues in GLP-1 receptor agonist therapy for type 2 diabetes
Zachary Bloomgarden
, Lawrence Blonde
, Alan Garber
, Carol Wysham
Icahn School of Medicine at Mount Sinai
Medicine
Medicine - Endocrinology, Diabetes and Bone Disease
Research output
:
Contribution to journal
›
Article
›
peer-review
6
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Current issues in GLP-1 receptor agonist therapy for type 2 diabetes'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
A1 Receptor
100%
Glucagon-like
100%
Receptor Agonist
100%
Agonist Treatment
100%
GLP-1 Receptor Agonist
100%
Clinical Management
16%
Insulin
16%
Patient Well-being
16%
Treatment Algorithm
16%
Quality of Life Satisfaction
16%
Hyperglycemia
16%
Glycemic Control
16%
Treatment Quality
16%
Type 2 Diabetic Patients
16%
Treatment Satisfaction
16%
Weight Effects
16%
Control Efficacy
16%
Type 2 Diabetes Mellitus Patients
16%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Glucagon-Like Peptide-1 Agonist
100%
Quality of Life
14%
Clinical Management
14%
Clinician
14%
Hyperglycemia
14%
Patient with Type 2 Diabetes
14%
Glycemic Control
14%
Pharmacology, Toxicology and Pharmaceutical Science
Glucagon Like Peptide 1 Receptor Agonist
100%
Maturity Onset Diabetes of the Young
100%
Hyperglycemia
14%